Connection
Andrea Griesinger to Prognosis
This is a "connection" page, showing publications Andrea Griesinger has written about Prognosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.246 |
|
|
|
-
Griesinger AM, Widener M, Donson AM, Mettetal A, Hankinson TC, Handler M, Mulcahy Levy JM, Lindsay HB, Macy ME, Foreman NK, Dorris K. Molecular biology and phase 1 study of GM-CSF and intrathecal trastuzumab in children with recurrent -posterior fossa ependymoma. Neuro Oncol. 2026 Jul 01; 28(7):1783-1793.
Score: 0.130
-
Witt DA, Donson AM, Amani V, Moreira DC, Sanford B, Hoffman LM, Handler MH, Levy JMM, Jones KL, Nellan A, Foreman NK, Griesinger AM. Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Pediatr Blood Cancer. 2018 05; 65(5):e26960.
Score: 0.072
-
Prince EW, Balakrishnan I, Shah M, Mulcahy Levy JM, Griesinger AM, Alimova I, Harris PS, Birks DK, Donson AM, Davidson N, Remke M, Taylor MD, Handler MH, Foreman NK, Venkataraman S, Vibhakar R. Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma. Oncotarget. 2016 Aug 16; 7(33):53881-53894.
Score: 0.016
-
Venkataraman S, Alimova I, Balakrishnan I, Harris P, Birks DK, Griesinger A, Amani V, Cristiano B, Remke M, Taylor MD, Handler M, Foreman NK, Vibhakar R. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15; 5(9):2355-71.
Score: 0.014
-
Hoffman LM, Donson AM, Nakachi I, Griesinger AM, Birks DK, Amani V, Hemenway MS, Liu AK, Wang M, Hankinson TC, Handler MH, Foreman NK. Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma. Acta Neuropathol. 2014 May; 127(5):731-45.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|